These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36382115)

  • 21. [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].
    Mao SS; Feng YJ; Xu L; Yao M; Xia Y; Jin JN; Wang LS; Chen TT; Chen XY; Zhang Y; Zhang H; Jiang Y; Li HB; Long Q; Gao F
    Zhonghua Er Ke Za Zhi; 2022 Jul; 60(7):688-693. PubMed ID: 35768357
    [No Abstract]   [Full Text] [Related]  

  • 22. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.
    Aragon-Gawinska K; Seferian AM; Daron A; Gargaun E; Vuillerot C; Cances C; Ropars J; Chouchane M; Cuppen I; Hughes I; Illingworth M; Marini-Bettolo C; Rambaud J; Taytard J; Annoussamy M; Scoto M; Gidaro T; Servais L
    Neurology; 2018 Oct; 91(14):e1312-e1318. PubMed ID: 30158155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
    Le Goff L; Seferian A; Phelep A; Rippert P; Mathieu ML; Cances C; de Lattre C; Durigneux J; Gousse G; Vincent-Genod D; Ribault S; Gomez Garcia de la Banda M; Quijano-Roy S; Sarret C; Servais L; Vuillerot C
    Neurol Sci; 2023 Jan; 44(1):329-337. PubMed ID: 36175810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
    Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
    Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study.
    van der Heul AMB; Cuppen I; Wadman RI; Asselman F; Schoenmakers MAGC; van de Woude DR; Gerrits E; van der Pol WL; van den Engel-Hoek L
    J Neuromuscul Dis; 2020; 7(3):323-330. PubMed ID: 32333596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort.
    Al-Zaidy SA; Kolb SJ; Lowes L; Alfano LN; Shell R; Church KR; Nagendran S; Sproule DM; Feltner DE; Wells C; Ogrinc F; Menier M; L'Italien J; Arnold WD; Kissel JT; Kaspar BK; Mendell JR
    J Neuromuscul Dis; 2019; 6(3):307-317. PubMed ID: 31381526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scientific rationale for a higher dose of nusinersen.
    Finkel RS; Ryan MM; Pascual Pascual SI; Day JW; Mercuri E; De Vivo DC; Foster R; Montes J; Gurgel-Giannetti J; MacCannell D; Berger Z
    Ann Clin Transl Neurol; 2022 Jun; 9(6):819-829. PubMed ID: 35567345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
    Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
    Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.
    Aragon-Gawinska K; Daron A; Ulinici A; Vanden Brande L; Seferian A; Gidaro T; Scoto M; Deconinck N; Servais L;
    Dev Med Child Neurol; 2020 Mar; 62(3):310-314. PubMed ID: 31799720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Electrophysiological Changes in Pediatric Spinal Muscular Atrophy after 2 Years of Nusinersen Treatment.
    Axente M; Mirea A; Sporea C; Pădure L; Drăgoi CM; Nicolae AC; Ion DA
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal natural history of type I spinal muscular atrophy: a critical review.
    Mercuri E; Lucibello S; Perulli M; Coratti G; de Sanctis R; Pera MC; Pane M; Montes J; de Vivo DC; Darras BT; Kolb SJ; Finkel RS
    Orphanet J Rare Dis; 2020 Apr; 15(1):84. PubMed ID: 32248834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scoliosis Orthopedic Surgery Combined With Nusinersen Intrathecal Injection Significantly Improved the Outcome of Spinal Muscular Atrophy Patient: A Case Report.
    Xu B; Wei C; Hu X; Li W; Huang Z; Que C; Qiu J; Li C; Xiong H
    Front Neurol; 2022; 13():869230. PubMed ID: 35547367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.
    Kotulska K; Chmielewski D; Mazurkiewicz-Bełdzińska M; Tomaszek K; Pierzchlewicz K; Rabczenko D; Przysło Ł; Biedroń A; Czyżyk E; Steinborn B; Pietruszewski J; Boćkowski L; Cichosz D; Dudzińska M; Gadowska E; Młynarczyk E; Jasiński M; Masztalerz A; Kempisty A; Kostera-Pruszczyk A
    Eur J Paediatr Neurol; 2022 Jul; 39():103-109. PubMed ID: 35738181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric SMA patients with complex spinal anatomy: Implementation and evaluation of a decision-tree algorithm for administration of nusinersen.
    Carrera-García L; Muchart J; Lazaro JJ; Expósito-Escudero J; Cuadras D; Medina J; Bosch de Basea M; Colomer J; Jimenez-Mallebrera C; Ortez C; Natera-de Benito D; Nascimento A
    Eur J Paediatr Neurol; 2021 Mar; 31():92-101. PubMed ID: 33711792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review.
    Ali I; Gilchrist FJ; Carroll WD; Alexander J; Clayton S; Kulshrestha R; Willis T; Samuels M
    BMJ Paediatr Open; 2019; 3(1):e000572. PubMed ID: 31909224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).
    Glanzman AM; McDermott MP; Montes J; Martens WB; Flickinger J; Riley S; Quigley J; Dunaway S; O'Hagen J; Deng L; Chung WK; Tawil R; Darras BT; Yang M; Sproule D; De Vivo DC; Kaufmann P; Finkel RS; ;
    Pediatr Phys Ther; 2011; 23(4):322-6. PubMed ID: 22090068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.
    Glanzman AM; Mazzone E; Main M; Pelliccioni M; Wood J; Swoboda KJ; Scott C; Pane M; Messina S; Bertini E; Mercuri E; Finkel RS
    Neuromuscul Disord; 2010 Mar; 20(3):155-61. PubMed ID: 20074952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data.
    Pane M; Coratti G; Sansone VA; Messina S; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Brigati G; Tacchetti P; Salmin F; de Sanctis R; Lucibello S; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Ann Neurol; 2019 Sep; 86(3):443-451. PubMed ID: 31228281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.